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Abstract 
 
Ventilator-associated pneumonia (VAP) is a consequence of intubation and mechanical 
ventilation.  Bacteria colonize the inner-lumen of endotracheal tubes (ETT) and develop 
into a biofilm.  One method to reduce/eliminate the develop of biofilms within the ETT is 
lining the inner-lumen with silver-sulfadiazine.  A systematic review was conducted to 
evaluate the effectiveness of silver-coated ETTs for patients that develop VAP.  Multiple 
databases were searched to identify key literature related to silver-coated ETTs and VAP.  
Inclusion and exclusion criteria were identified to finalize the studies that were included 
in this systematic review.  Five key studies were included in this review.  Studies were 
further evaluated with PRISMA, a data collection table, the Critical Appraisal Skills 
Programme (CASP) and the Critical Appraisal for Summaries of Evidence (CASE) 
worksheet.  All studies found either a reduction or elimination of bacteria within the ETT, 
breathing circuit, or lungs of the study subjects.  In addition to the reduced colonization 
found across the studies, one study found a reduction in the mortality rate for the 
intervention group following a diagnosis of VAP.  Certified Registered Nurse 
Anesthetists (CRNA) play an important role in educating staff about the impact silver-
coated ETTs have on patient outcomes throughout periods of intubation and mechanical 
ventilation.  Additionally, CRNAs are well positioned to identify patients pre-operatively 
that may require prolonged intubation following surgery.  By advocating for silver-coated 
ETTs for these patients, CRNAs can improve patient outcomes by reducing the 
likelihood of these patients developing VAP.   
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Ventilator-Associated Pneumonia and the Effectiveness of 
Endotracheal Tubes Coated with Silver Sulfadiazine 
Background/Statement of the Problem 
 
Ventilator-associated pneumonia (VAP) occurs when patients are mechanically 
ventilated and become colonized with bacteria in their endotracheal tube (ETT) that 
originates from an external source or gastric content.  Miller et al. (2014) defined VAP as 
occurring when a patient requiring mechanical ventilation develops a new lower 
respiratory infection.  Endotracheal tubes increase the risk of developing pneumonia by 
suppressing innate protective airway reflexes (Miller et al.).  Patients who develop VAP 
have increased length of hospitalizations and are intubated for a greater number of days.  
Additionally, those who develop VAP have more expensive hospitalizations, require a 
greater number of services from the multi-disciplinary hospital care teams and have a 
higher mortality rate than patients who do not develop VAP (Mietto, Pinciroli, Patel, & 
Berra, 2013).  Diagnosis of VAP includes a combination of new or persistent infiltrates 
on chest radiography and two of the following: temperature greater than 38.3, blood 
leukocytosis (>12 x 109 white blood cells/liter) or purulent tracheal secretions (Hunter, 
2012). 
The use of silver for treatment of bacterial infections, wounds and injuries is well 
established.  However, during the past several decades, its’ use has declined due to the 
development and availability of antibiotics (Rai, Yadav, & Gade, 2008).  As bacteria 
become increasingly resistant and harder to treat, silver’s antimicrobial properties have 
resurfaced as a viable option for the treatment and prevention of infections throughout the 
medical field. 
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One of the most frequently implicated sources of VAP are biofilms, which form 
on the inner-lumen of the ETT and have unimpeded access to patients’ lungs.  
Innovations to the design and composition of ETTs are being studied to determine 
efficacy in minimizing the development of VAP and biofilms.  Endotracheal tubes that 
utilize the impregnation or coating of silver sulfadiazine are designed to reduce the 
incidence of VAP by preventing the development of biofilm (Afessa et al., 2010).  
 Silver ions, with their ability to bind and oxidize Thiol groups and disrupt the 
development of respiratory-chain proteins, has been applied to ETTs as a treatment 
strategy to prevent bacterial colonization (Pirrone, Pinciroli, & Berra, 2016).  
Technological advances in the field of nanomedicine has renewed interest in metal 
impregnation, primarily silver, into medical devices (Palanisamy et al., 2014).  There is 
ongoing research involving the antimicrobial effects of silver on well known bacteria 
such as Escherichia coli, Staphylococcus Aureus, and Pseudomonas Aeruginosa.  The 
relationship between silver and nanomedicine uncovered direct links to the treatment of 
bacteria related to the size, shape, and composition of the silver particles’ efficacy of 
silver products on specific bacteria (Ge, Li, Wang, Ouyang, Li, & Xing, 2014). 
The purpose of this systematic review was to examine the impact of ETTs 
impregnated with silver sulfadiazine on patient’s with VAP.  The results will be 
compared to the incidence of VAP for patients with traditional polyvinyl-chloride ETTs. 
Next, the review of the literature will be presented 
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Literature Review 
           The review of literature was performed by accessing the databases Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), OVID and PubMed.  
Keywords used were ventilator-associated pneumonia, VAP, silver sulfadiazine, ETT, 
silver-coated endotracheal tubes and biofilm.  Dates searched were between 2006 and 
2017. 
Incidence and Cost of VAP 
The incidence of VAP is estimated to be 1.2%-8.5% per 1,000 ventilator days 
with the greatest risk of developing VAP during the first five days of intubation 
(Kalanuria, Zai, & Mirski, 2014).  Treatment and staffing for VAP are substantial.  Shorr, 
Zilberberg, & Kollef found that it cost $12,840 for each patient diagnosed with VAP.  
Zimlichman et al. suggested the development of VAP, which is the second most 
expensive nosocomial infection, cost $40,144 (2013). 
Prevention of VAP is a national patient safety standard.  The Centers for 
Medicare and Medicaid services has proposed non-reimbursement for healthcare centers 
where patients are diagnosed with VAP (Mietto, Pinciroli, Patel, & Berra, 2013).   
Ventilator-Associated Pneumonia and Intubation 
The development of VAP occurs mainly from the ETT obstructing the body from 
coughing to protect itself (Kalanuria et al., 2014).  The body’s inability to expectorate 
potentially infectious pathogens allows them to penetrate deep into the oropharynx.  
Ventilator-associated pneumonia is described by Kalanuria et al. as a “complex interplay 
between the endotracheal tube, patient risk factors, virulence of invading organisms, and 
the host’s immunity” (p. 1).  Additional contributing factors include supine positioning, 
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enteral feedings through naso/orogastric tubes and trauma (Hunter, 2012).  One of the 
common sources of bacterial introduction to the lungs occurs during direct laryngoscopy, 
which leads to micro-aspiration (Kalanuria et al., 2014).   
Following intubation, the cough reflex of the glottis and larynx is inhibited.  
Pathogens located within the oral cavity start to adhere to the inner lumen of the standard 
polyvinyl chloride (PVC) ETT.  When patients remain intubated and ventilated, bacteria 
begin to form a microfilm within the ETT which ultimately develops into an endoluminal 
biofilm.  These pathogens, some of which can lead to VAP, migrate to the lower 
respiratory tract (Pirrone et al., 2016).   
Following cuff inflation of the ETT, secretions begin to pool in the subglottic area 
surrounding the cuff and ultimately seep into the lungs (Kalanuria et al., 2014).  The 
secretions constantly ooze around the cuff through microscopic folds known as micro-
channels (Pirrone et al., 2016).  The combination of endoluminal biofilms and pathogenic 
secretions leaking into the lower respiratory tract via micro-channels significantly 
increase the risk of VAP.   
 One of the key determinants in a pathogen’s etiology of VAP is the length of time 
the patient has been intubated.  Kalanuria et al. (2014) found that patients diagnosed with 
VAP shortly after intubation were more sensitive to antibiotics.  Patients diagnosed with 
late-onset VAP were more difficult to treat because the causative pathogens were often 
multi-drug resistant.  Streptococcus Pneumonia, Hemophilus Influenza, Methicillin-
sensitive Staphylococcus Aureus (MSSA), Escherichia Coli and Klebsiella Pneumonia 
were identified as common pathogens found in early-onset VAP (Kalanuria et al.).  
Common pathogens identified for late-onset VAP include Methicillin-resistant Staph 
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Aureus (MRSA), Pseudomonas Aeruginosa, and Extended-Spectrum Beta-Lactamase 
(ESBL) (Kalanuria et al.).   
Prevention and diagnosis of VAP remain challenging for medical professionals.  
One of the challenges in diagnosing VAP is that there is no recognized diagnostic gold 
standard.  Bedside evaluation and chest x-ray are effective diagnostic tools but are not 
definitive (Kalanuria et al., 2014).  Although chest x-rays are frequently used as a 
diagnostic tool for VAP, other conditions such as acute respiratory distress syndrome 
(ARDS), congestive heart failure (CHF) and aspiration pneumonitis have similar 
radiological appearances.  The recommendation for diagnosis of VAP by the Infectious 
Diseases Society of America (IDSA) and the American Thoracic Society (ATS) is to 
obtain and culture tracheal aspirates or lower respiratory tract samples (Kalil et al., 2016). 
The leading strategy for prevention of VAP remains VAP bundles (Hunter, 2012).  
Ventilator associated pneumonia bundles are evidence-based interventions that promote a 
prophylactic approach to preventing VAP by reducing the likelihood of aspirating 
contaminated secretions and limiting the pulmonary colonization of bacteria.  Ventilator 
associated pneumonia bundles include elevation of the head of the bed, prophylaxis stress 
ulcer medication, deep venous thrombosis prophylaxis, oral care with chlorhexidine and 
daily sedation assessments that monitor breathing status (Kalanuria et al., 2014).  In 
addition to basic VAP bundles, some additional strategies to reduce VAP include 
thorough oral care every 2-4 hours with chlorhexidine, frequent oropharyngeal 
suctioning, inline ETT suctioning, and removal of condensation that develops throughout 
the ventilator circuit (Miller et al., 2014).  
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Due to the significant morbidity and mortality of VAP, the Institute for 
Healthcare Improvement (IHI) created a campaign in 2005 called the 100,000 lives 
campaign that included implementing VAP bundles as one of the core initiatives to 
minimize adverse patient outcomes.  The IHI’s goal was to save 100,000 lives in 18 
months through six evidence-based clinical interventions (IHI, n.d.).  During a follow up 
study to the 100,000 lives campaign (2009), Bigham et al. concluded that there had been 
significant reductions in VAP, length of intubation and mechanical ventilation and length 
of hospital stay since the implementation of VAP bundles.  As a result of the IHI’s 
successful campaign to prevent incidences of medical harm and to improve patient health 
outcomes, the campaign expanded its goal to 5,000,000 (IHI, n.d.).  Despite the belief by 
medical experts that the campaign was successful, the IHI has not been able to accurately 
calculate and quantify the data (IHI, n.d.).  The IHI continues to stress the need for 
hospital compliance with VAP bundles (Kalanuria et al., 2014).   
A new proposal that has gained traction in VAP prevention is single dose 
antibiotic therapy within four hours of intubation (Kalanuria et al., 2014).  While this 
strategy has spurred interest, no randomized clinical trials have been completed to 
support the theory that it could reduce VAP.  As the research surrounding VAP advances, 
the focus on prevention has grown to include strategies to minimize its morbidity, 
mortality, and impact on the health care system.  One key area of research regarding VAP 
reduction is silver technology.  Silver’s well established use as an antimicrobial and 
treatment option for burns has advanced into a multitude of silver products. 
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Silver Sulfadiazine and General Medical Use 
One of the roles of silver in healthcare is to minimize the potential of infection 
associated with medical devices.  Nearly half of all nosocomial infections are caused by 
hip prosthetics, vascular and urinary catheters, and ETTs (Monteiro et al., 2009).  Due to 
increasing rates of nosocomial infections and drug resistant bacteria, silver has seen 
renewed interest and implementation within the medical field (Wan et al., 2016).  
Advancements in nanotechnology and infectious disease research have shown 
increasingly effective treatment for highly resistant infections, such as carbapenem-
resistant, by adding silver nanoparticles to antibiotic regimens (Wan et al.).  The addition 
of silver also allows providers to dose patients’ antibiotics more conservatively.  Lower 
doses of antibiotics reduce the likelihood that a patient will receive harmful or toxic doses 
or antibiotics.  
The antimicrobial properties of silver have been used to treat burn injuries for 
more than 200 years (Marx & Barillo, 2014).  Silver inhibits bacteria by binding to the 
base pairs of the DNA helix (Rai et al., 2009) which prevents transcription and causes 
damage to the cell membrane.  Silver, in particular Nanosilver particles (NSP), have 
broad antimicrobial properties against both gram negative and gram positive bacteria (Ge 
et al., 2014).   Nanoparticles are small clusters of atoms ranging from 1-100 nanometers 
(Rai et al., 2009).  Nanosilver particles can be impregnated into medical devices, 
nanogels and nanolotions.  Nanosilver particles are used for diagnosis, drug delivery and 
treatment of infections.  In addition to NSPs antibacterial qualities, silver has also been 
used as an antiviral, antifungal, and anti-inflammatory (Ge et al., 2014).   The key factors 
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that influence the efficacy of silver particles as an antimicrobial agent include size, shape 
(rods, particles, plates), and concentration (Ge et al.).  
Other promising silver products besides NSPs include silver zeolite (SZ) and 
products that release silver in their oxidized form (Monteiro et al., 2009).  Silver ions are 
very effective at inhibiting bacterial growth by inactivating the Thiol group within a 
protein.  The ions disrupt DNA replication by disrupting the transport chain and 
uncoupling the oxidative phosphorylation leading to complications with cell permeability 
(Duran et al., 2016).  Silver zeolites provide a large surface area that makes ion release 
much easier to control (Leyland et al., 2016).  Additionally, the total amount of silver in 
the zeolites is modest which makes it financially reasonable as an adjunct/form of 
treatment.  
Nanomedicine, including NSPs, is an important trend in modern medical 
treatment.  Due to its emergence as an adjunct or alternative to certain antibiotic 
treatments, silver nanomedicine has drawn the interest of many scientific and infection 
control specialists (Franci et al., 2015).  The importance of nanotechnology and silver is 
that they possess a large surface to area to volume ratio (Rai et al., 2009).  The surface to 
volume ratio makes nanoparticles increasingly intriguing for researchers who study 
treatment modalities for microbes that are resistant to metal ions (Rai et al.).  This ratio 
creates an effective treatment strategy against bacteria.  Released silver ions possess 
significant antimicrobial properties in vivo and in vitro.   
One limitation to the effectiveness of silver for use as an antimicrobial is that it 
has a concentration-dependent toxicity for humans (Brandt et al., 2012).  Percutaneous 
absorption of silver can lead to argyria.  Argyria is a local or systemic tissue deposition of 
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silver (heavy metal) in organs such as the liver, spleen or kidney or nerves that can lead 
to organ failure (Brandt et al.).  Another limitation is microbial resistance to silver.  
Several silver resistant bacteria have been identified globally throughout India, Utah, and 
the United Kingdom (Duran et al., 2015).  Overuse of silver nanoparticles as an 
antimicrobial could lead to a new generation of microbial resistance.  
Silver Coated Endotracheal Tubes (ETT) and VAP 
Biofilms are antimicrobial resistant areas of bacterial colonization that proliferate 
in moist areas (Monteiro et al., 2009).  Biofilm leads to VAP by creating a network of 
secretions and attached microorganisms capable of migrating along the ETT cuff polymer 
down the inner lumen of the ETT (Fernandez, Levine, & Restrepo, 2012).  Biofilms are a 
target area of study for silver scientists.  Fernandez et al. described why biofilm research 
is critical to reducing VAP.  A characteristic of biofilms that makes them amenable to 
treatment with silver is that they are capable of extracting minerals and metals up to a 
quantifiable absorption capacity.  Factors that are used to quantify absorption capacity 
and binding affinity are the size/charge ratio, the bacterial polysaccharide charge, the pH, 
and the biofilm (Moneiro et al., 2009).  As the biofilm absorbs the silver, its development 
is inhibited.  
              One of the key pieces of literature and landmark studies related to silver 
sulfadiazine and ETTs was The North American Silver-Coated Endotracheal Tube 
(NASCENT) Randomized Trial (Kollef et al., 2008).  This prospective, randomized, 
single-blind trial was conducted in North America between 2002-2006 and involved 54 
locations and 2,003 patients that required mechanical ventilation for a minimum of 24 
hours.  The primary outcome measure for the study was incidence of VAP. 
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The only inclusionary criteria was that patients had be at least 18 years-old and 
required intubation for at least 24 hours.  Exclusionary criteria included current 
participation in another study, cystic fibrosis, hemoptysis, pregnancy, silver sensitivity 
and intubation within the past 30 days.  Screening for the trial included 9,417 potential 
participants.  Screening and data collection focused on patients’ demographics, medical 
history, immunocompetency and Acute Physiology and Chronic Health Evaluation 
(APACHE) II.  The APACHE II is a scoring system used in intensive care units (ICU) 
that classifies each patient’s severity of illness.  Of the 9,417 patients screened, 7,414 
were deemed ineligible.  Of the remaining 2,003, 71 ended up not requiring intubation 
and 423 were intubated for less than 24 hours.  Each patient was intubated with a high 
volume-low pressure ETT.  During the study, specific patient data collection included 
daily chest radiographs, clinical signs of VAP, adverse events, length of stay in the ICU 
and hospital, mortality, antibiotics used during bronchoalveolar lavage (BAL), oral care, 
tracheal suctioning and method of nutrition delivery (Kollef et al.). 
Results from the study identified a relative risk reduction in VAP of 34.2% for 
patients intubated with ETTs coated with silver sulfadiazine (Kollef et al., 2008).  Of the 
patients intubated with the silver-coated ETT, 4.8% were diagnosed with VAP (37/766).  
Patients with the uncoated-traditional ETT were diagnosed with VAP 7.5% of the time 
(56/743).  The findings were supported by a 95% confidence interval (CI) and a 90% 
statistical power.  Secondary findings by Kollef et al. included a delayed occurrence of 
VAP as well as a relative risk reduction in the frequency of VAP diagnosed for patients 
intubated with silver-coated ETTs for greater than 10 days.  Patients with the silver-
coated ETTs had a mortality rate of 30.4% (233/766) while patients intubated with 
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standard ETTs had a mortality rate of 26.6% (198/743).  Interestingly, there was no 
statistical difference in the frequency or severity of adverse events in in either group 
(Kollef et al.).   
 Another key piece of literature involving silver-coated ETTs is the Association 
Between a Silver-Coated Endotracheal Tube and Reduced Mortality in Patients with 
Ventilator-Associated Pneumonia by Afessa et al. (2010).  In this retrospective study of 
the NASCENT randomized trial, Afessa et al. analyzed the data from the NASCENT 
study.  The purpose was to identify an association between decreased mortality in 
patients diagnosed with VAP when silver-coated ETTs were used compared to traditional 
ETTs.   
The results supported the original findings from the NASCENT study.  Afessa et 
al. (2010) concluded that ETTs impregnated with silver sulfadiazine not only reduced 
incidences of VAP, but it also reduced mortality in patients with VAP.  The mortality rate 
for patients diagnosed with VAP that had silver-coated ETTs was 5 out of 37 (14%) 
while the mortality rate for patients without the silver-coated ETT was 20 out of 56 
(36%).  The P value for the findings was 0.03.  This implies a significant difference in 
patient outcomes based on what type of ETT was used.  The mortality rate for the 
patients who did not have VAP was 228/729 (31%) for patients with the silver-coated 
ETTs and 178/687 (26%) for patients without the silver-coated ETTs.  Although no 
significant conclusions were made regarding mortality in the group that did not develop 
VAP, respiratory failure, multi-organ failure, and sepsis were most frequently cited as 
their cause of death (Afessa et al.).  
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 Studies involving silver coated ETTs are limited.  However, there have been 
several in vitro and animal studies.  Many of the in vitro and animal studies have shown 
effective preventative strategies and antimicrobial properties with silver. 
           Next, the theoretical framework that guided the project will be discussed. 
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Theoretical Framework 
 
The Preferred Reporting Items for Systematic Review and Meta-Analysis 
Protocols (PRISMA-P) is a data reporting system used for systematic reviews.  The goal 
of PRISMA is to provide both the reader and the researcher/author transparency and 
consistency while evaluating data for both systematic reviews and meta analysis.  
Systematic reviews and meta-analyses are considered by many to be the gold standard for 
collection, interpretation, and dissemination of research in health care (Moher, Liberati, 
Tetzlaff, & Altman, 2009).  Systematic reviews are becoming increasingly common 
throughout healthcare due to their methodological rigor (Moher et al., 2015).  As of 2010, 
11 new systematic reviews were published daily (Moher et al., 2015).   
In 1999, before PRISMA-P, the Quality of Reporting of Meta-Analysis 
(QUOROM) was developed in response to suboptimal reporting of meta-analyses (Moher 
et al., 2009).  The QUOROM statement was developed by an international group who 
believed that prior systematic reviews and meta-analyses were of inferior quality and 
poorly presented.  As systematic reviews and meta-analyses became more popular, the 
QUOROM statement was redesigned into PRISMA.  
The Preferred Reporting Items for Systematic Review and Meta-Analysis was 
originally designed in 2005 for authors who needed a consistent framework to collect and 
report data from systematic reviews and meta-analysis.  Improved reporting through 
PRISMA helped readers with decision making and clarity to evaluate the quality of 
research being presented (Moher et al., 2009).  One aspect of systematic reviews that was 
felt to be lacking throughout research in healthcare was clarification and consistency.  
Protocols identified by PRISMA aimed to help authors clarify and identify relevant topics 
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and explicitly document on their specified topics (Moher et al.).  As a result, PRISMA 
lead to more consistency, integrity, and accountability (Moher et al.).   
The Preferred Reporting Items for Systematic Review and Meta-Analysis 
incorporates a 27 item checklist to guide researchers and minimize bias in data 
compilation.  The checklist includes seven major headings that consist of title, abstract, 
introduction, methods, results, discussion, and funding.  The checklist allows researchers 
to compile data in a consistent and transparent format. The Preferred Reporting Items for 
Systematic Review and Meta-Analysis was used to guide the researcher through the 
process of completing a thorough systematic review. 
The author reviewed the 27 item checklist created by PRISMA to organize and 
compile data.  The organization and compilation of data provided in-depth extrapolation 
of findings for the reader.  For example, data gathered by the author for the results section 
will inform readers of each studies characteristics, potential bias, and individual results.  
The author identified limitations of each study and completed the critical appraisal 
process. 
 The Preferred Reporting Items for Systematic Review and Meta-Analysis also 
contains a flowchart (Figure 1) to aid researchers throughout their literature review 
process for evaluation of research as it relates to specific topics.  The flowchart provides 
readers with a visual as to how the data is collected and utilized.  Each phase of process 
including identification, screening, eligibility, and inclusion are clearly documented for 
the reader.   
 The critical appraisal was completed by using the tool created by the Better Value 
Healthcare Ltd (BVHC) called the Critical Appraisal Skills Programme (CASP).  The 
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CASP was created by a group from Oxford, England which focuses on value based 
healthcare for individuals and organizations.  The group, also known as the Public Health 
Resource Unit, is part of the National Health Service (NHS) in England.  The Critical 
Appraisal Skills Programme was designed to aide professionals who desire to use 
research in their professional practice.  Additionally, CASP can be used to help develop 
guidelines and industry policy.  One key focus of CASP is to help readers better 
understand and utilize scientific data/results.  The BVHC provides training courses, 
education and training materials, and works with healthcare providers to improve their 
understanding and value related to patient care.   
The Critical Appraisal Skills Programme can aide and expedite the researcher 
who is compiling data during a systematic review by asking three straight-forward 
questions: 
1).  Is the study valid?  
It is important to identify if there was any bias in the study.  One of the 
most effective methods to identify bias in a study is to analyze the quality of the 
methods used. 
2).  What are the results? 
If the study is determined to be valid, the results may be considered.  
When reviewing the results, it is imperative to identify any ambiguity in the 
findings.  Additionally, the results should be examined for clinical significance.   
3).  Are the results useful? 
If the study is unbiased and the results are valid, a determination must be made 
regarding the usefulness of the results.  A determination must be made regarding the 
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application of the findings to the author’s original question.  These three questions help 
researches quickly critically appraise research and make their own determination of the 
studies quality.  
 If the study is determined to be valuable, CASP identifies an additional 10 
questions that help the researcher systematically analyze each study.  The first two 
questions are screening questions.  If the answer to both of the first questions is “yes,” the 
researcher should continue with the remaining questions.  
1. Did the review address a clearly focused question? 
2. Did the authors look for the right type of papers? 
3. Do you think all the important, relevant studies were included? 
4. Did the review’s authors do enough to assess the quality of the included 
studies? 
5. If the results of the review have been combined, was it reasonable to do so? 
6. What are the overall results of the review? 
7. How precise are the results? 
8. Can the results be applied to the local population? 
9. Were all important outcomes considered? 
10. Are the benefits worth the harms and costs? 
The cross study analysis was further clarified by utilizing the Critical Appraisal 
for Summaries of Evidence (CASE) worksheet for systematic reviews.  This tool, created 
by Foster and Shurtz in 2013, was designed to systematically assess the overall quality of 
evidence presented in each study.  Pertinent topics covered in the worksheets include 
topic, method, content, and application to practice.   
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 Next, the study methods will be described. 
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Method 
 
Purpose 
            
The purpose of this systematic review was to examine the impact of ETTs  
 
impregnated with silver sulfadiazine on patient’s with VAP.  
 
Inclusionary and Exclusionary Criteria 
Inclusion criteria included: human subjects that are at least 18 years-old who were 
intubated for a minimum of 24 hours in an ICU; all specialty care ICUs except pediatric 
and neonatal; ETTs must have been coated or impregnated with silver sulfadiazine in an 
intervention group with uncoated ETTs in a control group; must have been diagnosed 
with VAP.  Animal studies involving intubations with silver coated ETTs were also 
included.  Animal trials were included due to their similarities in study design and 
controls that paralleled human trials.  The author focused primarily on randomized 
controlled trials (RCT).  No limitations were set for dates of articles.  Only articles 
available in English were included. 
Exclusionary criteria included patients with significant hemoptysis (hemoptysis 
automatically places patients at high risk for aspiration and the development of 
pneumonia), patients who were previously intubated within the past 30 days (they are 
respiratory compromised) and patients intubated for 14 days or greater. 
Data Collection Strategy  
 Data collection included information specific to the study design (Table 1).  These 
pieces of data were collected and organized using a tool to provide a clear and concise 
visualization for the author when referencing key literature.  Data collection also included 
data that focused on study outcomes.  The collection and sorting process helped guide the 
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author so that studies could be quickly referenced.  Breaking down the data provided the 
author a clear way to compare and contrast the studies throughout the data synthesis 
Table 1   
Data Collection Template 
Study 
Design 
Site 
Sample 
(age, 
number of 
participants 
-how they 
were 
selected, 
human or 
animal 
subjects) 
Patient risk 
factors 
prior to 
intubation 
(i.e. 
existing 
heart 
disease, 
immunode-
ficiency, 
chronic 
obstructive 
pulmonary 
disease 
(COPD) 
Duration 
of 
Intubation 
Was the 
ETT coated 
or 
impregnated 
with silver 
sulfadiazine 
or was it an 
uncoated 
ETT? 
Outcomes of 
intubation?  
Mortality rate 
for 
participants 
diagnosed 
with VAP. 
Limitations 
 
The author critically analyzed the selected studies with the CASP tool for 
systematic reviews.  The author focused on such items as the quality of the study design, 
quality of data, the relevance of the data and the implications of how the data can be 
used. 
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The goal of the data synthesis was to provide a method for the author to look 
across the studies and determine if commonalities or variations were found throughout 
the available data.  The Critical Appraisal for Summaries of Evidence (CASE) worksheet 
for systematic reviews was used to compare across studies.  The author then examined 
across all studies to identify commonalities and variances throughout the descriptive data 
synthesis.  It was critical to determine if the results of the studies supported or refuted 
each other. 
Next, the study results are presented. 
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Results 
 
Based on the inclusion and exclusion criteria, the systematic review included five 
studies.  The pathway that resulted in the selection of the studies is illustrated in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  The Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
Flow Diagram. 
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The data collection tables are presented in Appendix A, with each of the five 
studies individually numbered.  The critical appraisal of each study is presented in 
Appendix B. 
            The study conducted by Berra et al. (2004; Appendix A-1) was a randomized 
controlled trial conducted at the National Institutes of Health Animal Research 
Laboratory in Bethesda, Maryland.  The authors examined whether or not ETTs coated 
with antiseptics (silver) would decrease bacterial colonization of ventilator circuits, lungs, 
and ETTs.  Subjects were female Dorset sheep (N=16) that were intubated for 24 hours 
and ranged in weight from 25-37 kg.  The intervention group (n=8) were intubated with 
silver-coated ETTs and the control group (n=8) were intubated with standard ETTs.  Each 
subject was considered to be in optimum health prior to the study.  Based on laboratory 
data and chest radiographs taken three days before the start of the study, no 
predetermined risk factors were identified.  No antibiotics had been given to the subjects 
within four weeks of the study’s start. 
Each subject was successfully intubated on the first attempt.  Subjects were 
placed in the prone position during the 24-hour mechanical ventilation period.  
Throughout the study, the subjects were monitored for respiratory and hemodynamic 
parameters/changes, core body temperature, arterial blood gases, and urine output.  
Microbiologic sampling was conducted every eight hours and included blood samples 
and a swab of the internal lumen of the ETT.  Mucus and secretions gathered from the 
ETT were gram-stained and analyzed with light microscopy.  During the study, subjects 
were afebrile and not found to have developed leukocytosis or changes in chest 
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radiographs.  No parenteral nutrition, IV fluid replacement, or antibiotics were 
administered during the study.    
 Results of the study were collected from autopsy and the subject’s equipment 
(ETT and ventilator circuit).  Tissue samples were gathered from the trachea, larynx, 
bronchi and the five lung lobes of each subject.  Of the subjects with the silver-coated 
ETTs (intervention group), seven out of eight were free of bacterial colonization 
throughout the ETT.  The subjects intubated with standard ETTs (control group) had 
extensive bacterial colonization of their lower respiratory tract, ETT and ventilator 
circuit.  Multiple bacterial species were found in the tracheal-bronchial tree and lungs of 
both groups.  The bacteria were found in three out of eight in the intervention group and 
seven out of eight in the control group were colonized (P=0.119).    
One of the limitations to extrapolating further data from this study was that all 
subjects were euthanized following the 24 hours of mechanical ventilation.  Due to the 
euthanization, readers can only speculate which of the subjects would have developed 
VAP.  While the likelihood is high that all the bacterially colonized subjects would have 
developed VAP, no conclusions can be made. 
This study was critically appraised using the CASP tool (Appendix B-1).  The 
study addressed a specific question regarding effectiveness of silver-coated ETTs and 
bacterial colonization of the lungs, ETT and ventilator circuit.  The study appropriately 
randomized subjects and blinded staff involved with the study.  Subjects were similar in 
overall health at the start of the study, treatments were consistent between both the 
control and intervention groups, and all were accounted for in the results.  No treatment 
effect was documented.  Although the study participants were sheep, the results were 
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comparable to those of human studies.  All important outcomes were identified and 
considered during the study.  Although the data gathered from the study supported similar 
studies, it is unclear if the harms/costs of the study were beneficial because all 
participants were euthanized following the 24 hours of mechanical ventilation. 
             The study conducted by Berra et al. (2008; Appendix A-2) was a randomized 
controlled trial that was performed on eight Dorset sheep that were mechanically 
ventilated for a period of 24 hours.  All study participants were deemed healthy prior to 
the study.  Each had undergone multiple screening tests including labs, chest radiographs 
and clinical examinations.  Additionally, each was intubated successfully on the first 
attempt.  The study was conducted in a laboratory at the National Institute of Health in 
Bethesda, Maryland.  Four sheep were intubated with silver-coated ETTs (intervention 
group) and the remaining were intubated with standard polyurethane ETTs (control 
group). 
Presence of colonization was determined by taking biopsies during autopsy.  A 
total of 12 biopsies of 50 mg each were collected from various sites including the five 
lung lobes, five lobar bronchi, 2 centimeters superior to the carina and one from the 
trachea at approximately the midpoint of the ETT.  Extensive colonization was found in 
the lower respiratory tract (p < .01) of the sheep who were intubated with standard ETTs 
as compared to those in the control group.  Although the colonization was most abundant 
in the lower respiratory tract, it was also present throughout the breathing circuit of the 
ventilator tubing (p = 0.003) of the control group sample.   
The study did have several limitations, including the small sample size of eight 
participants.  Another limitation of the study was that the results were presented in 
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difficult to comprehend format (ex: 5.0 × 105– 4.5 × 108).  Presenting results/data in this 
type of format limits the audience that can utilize and interpret the results.  In order to 
understand and utilize the data, readers need to spend more time than expected to find 
supportive data for their own use. 
This study was critically appraised using the CASP tool (Appendix B-2).  The 
study, a randomized controlled trial, addressed the question of whether or not silver-
coated ETTs could effectively prevent bacterial colonization of the respiratory tubing and 
lower respiratory tract.  All subjects were similar at the start of the study and accounted 
for in the results.  Unfortunately, it is not clear if all experimental interventions were 
consistent between the control group and intervention group.  Additionally, there were no 
specifics reporting how the health workers were blinded during treatment/interventions.  
No treatment effect was reported.  Results of the study were similar to results of human 
studies.  However, it is not clear whether or not the results from this study can be applied 
to human studies.  It is unclear if all important outcomes were considered because 
subjects were euthanized following the study.  Euthanization prevented subjects from 
fully developing VAP.  It is unclear if the benefits outweigh the costs/harm caused by this 
study.  Euthanization and animal studies is an ethical question that can only be answered 
on an individual basis.       
 The study conducted by Rello et al. (2006; Appendix A-3) was a single blind 
randomized controlled trial that focused on whether or not reducing bacterial airway 
colonization with silver-lined ETTs was effective.  The study was conducted at four 
hospitals.  One hospital was in the United States and three were in Spain.  In order to 
qualify for the study, participants had to be at least 18 years old, intubated for a minimum 
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of 24 hours and be a patient in the intensive care unit (ICU).  One hundred fifty-five were 
screened for the study but only 121 were entered in the study. The 34 that were not 
entered in the study were either intubated for less than 24 hours or not intubated at all.  
The intervention group (silver-coated ETTs) consisted of 61 participants and the control 
group (standard ETTs) consisted of 60 participants.  The mean age was 64.6.  
The authors identified significant patient risk factors that increased the likelihood 
of participants developing VAP including previous intubations, recent surgery, trauma 
patients, use of muscle relaxants (paralytics), continuous sedation, smoking coma, and 
alcohol abuse.  Nineteen participants from the intervention group and 28 from the control 
group had at least one of these risk factors.  Additional risk factors identified in study 
included enteral nutrition, parenteral nutrition and antibiotic exposure within the previous 
14 days.  Of the 61 participants in the intervention group, 42 received enteral nutrition, 12 
received parenteral nutrition and 32 had received antibiotics within the previous 14 days. 
Of the 60 participants in the control group, 45 received enteral nutrition, 8 received 
parenteral nutrition and 30 had received antibiotics within the previous 14 days.   
The authors concluded that the silver-coated ETT was effective at reducing 
bacteria in tracheal aspirates and increasing the time it takes for the inter-lumen of the 
ETT to become colonized with bacteria.  The most significant finding was delayed inter-
lumen colonization of the silver-coated ETTs (p 0.02) compared to the standard ETTs 
(3.2 days for silver ETTs vs 1.8 days for standard ETTs).   
Limitations of the study included lack of “blinding” the ICU staff.  The ICU staff 
knew which patients had silver-coated ETTs and which had standard ETTs.  This 
provides a potential for bias and could have impacted how they provided oral care, 
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suctioning, etc.  Additionally, the infection control process was not standardized between 
the four hospitals.  Lack of standardization could have a significant impact on 
outcomes/results.   
This study was critically appraised using the CASP tool (Appendix B-3).  This 
single-blind study addressed whether a silver-coated ETT could feasibly and safely 
reduce bacterial colonization of the lungs and tracheal aspirates.  All participants who 
entered the study were accounted for and all relevant clinical outcomes were reported.  It 
is not clear if the control group and intervention group were similar at the start of the trial 
because only baseline characteristics and demographics were provided.  Unfortunately, 
healthcare workers were not blinded during treatments or data collection and treatment 
standards varied amongst the four facilities.  No treatment effect was reported.  It is 
unclear if the results of this trial could be applied to similar studies due to the lack of 
standardization among the four facilities (potential for bias).  The benefits of the Rello et 
al. study outweigh the risks/costs.  No adverse outcomes were reported.   
 The NASCENT study conducted by Kollef et al. (2008, Appendix A-4) was a 
prospective, randomized, single-blind study.  The study was conducted between 2002-
2006 at 54 medical centers throughout North America.  There were 9,417 patients 
screened for the study and of those, 2,003 were expected to require mechanical 
ventilation for at least 24 hours.  Ultimately, the study involved 1,509 intubated 
participants.  Of those, n=766 were intubated with the silver-coated ETT (intervention 
group) and n=743 were intubated with the standard ETT (control group). 
 Significant risk factors identified prior to the study were smoking, 
immunodeficiency and Chronic Obstructive Pulmonary Disease (COPD).  The number of 
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study participants who smoked was 234.  Of the 234 smokers, 121 were intubated with 
the silver-coated ETT (intervention group) and 113 were intubated with the standard ETT 
(control group).  Of the 370 immune-deficient participants in the study, 184 were 
intubated with the silver-coated ETT (intervention group) and 186 were intubated with 
the standard ETT (control group). The number of participants who had COPD was 211.  
Of the 211 with COPD, 89 were intubated with the silver-coated ETT (intervention 
group) and 122 were intubated with the standard ETT (control group).   
 Results of the study (microbiologically confirmed cases of VAP) were a 4.8% 
incidence of VAP for the participants intubated with the silver-coated ETT (n=37) and a 
7.5% incidence of VAP for participants intubated with the standard ETT (n=56).  These 
findings had a 95% confidence rating.  The findings suggest a 35.9% relative risk 
reduction in the development of VAP for participants intubated with silver-coated ETTs 
compared to the standard ETTs when intubated for a minimum of 24 hours.  Participants 
with silver-coated ETTs were found to have a substantial reduction in microbiologically 
confirmed cases of VAP compared to the control group.  
An additional finding was a delayed onset of VAP for participants intubated with 
the silver-coated ETT compared to the standard ETT.  After 10 days on intubation, only 
27/766 (intervention group) had developed VAP while 50/743 (control group) had 
already been diagnosed with VAP (P=0.005).  
One of the limitations of this study was that it was limited to patients who could 
consent for themselves.  This precludes a large amount of potential participants who 
required intubation such as patients in respiratory distress who require emergent 
intubation or patients who have altered mental status and can’t self-consent.  These 
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patients are highly susceptible to the development of VAP and would have been valuable 
to include in the study. 
This study was critically appraised using the CASP tool (Appendix B-4).  The 
prospective, randomized, single-blind study clearly focused on whether or not a silver-
coated ETT would reduce the incidence of microbiologically confirmed VAP.  All 
clinically important outcomes from the study were reported including VAP diagnosis and 
onset of VAP.  Participants in the study were similar at the start of the trial, treatments 
throughout the trial were consistent, and all were accounted for in the results.  Study 
personnel were blinded to control/intervention group.  The treatment effect was a 35.9% 
relative risk reduction in incidence of VAP.  Results from the Kollef et al. study can be 
applied to the local population.  The benefits outweigh the harms/costs as no adverse 
outcomes were reported. 
 The study conducted by Afessa et al. (2010; Appendix A-5) was a retrospective 
cohort analysis of patients from the NASCENT trial who had developed VAP.  Afessa et 
al. applied a stepwise multivariate logistic regression on the patients from the NASCENT 
study (N=93) that developed VAP to determine whether or not there was a reduced 
mortality rate when a silver-coated ETT was used instead of the standard ETT.   
 Of the 93 patients, 37 were intubated with a silver-coated ETT (intervention 
group) and 56 were intubated with the standard ETT (control group).  The mean age of 
the intervention group was 59.8.  The mean age of the control group was 63.3.  There 
were no significant demographic differences between the two groups. 
Significant patient risk factors identified by the authors included COPD, 
immunodeficiency, emergent surgery/trauma, inappropriate antibiotic administration, and 
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coma.  The intervention group contained five COPD patients, eight immunodeficient 
patients, and three that required emergent surgery or were involved in a trauma.  The 
control group contained seven COPD patients, nine who were immunodeficient, six that 
required emergent surgery or were involved in a trauma, nine that had received 
inappropriate antibiotics and one in a coma.   
Results from the retrospective cohort analysis found a mortality rate of 14% for 
patients in the intervention group that developed VAP (n=5).  The mortality rate for 
patients in the control group that developed VAP was 36% (n=20) (p=0.03) (CI 95%).  
The authors concluded that the only variable that altered mortality rate was whether 
patients were in the intervention group (silver-coated ETT) or the control group (standard 
ETT). 
Another significant finding was a reduction in the development of multidrug 
resistant bacteria for patients in the intervention group as compared to those in the control 
group.  Of the 37 patients in the intervention group, 13 were diagnosed with bacterial 
infections that were considered multidrug resistant (approximately 35%).  Of the 56 
patients in the control group, 25 (45%) were diagnosed with bacterial infections that were 
considered multidrug resistant.  There was a 29% reduction in multidrug resistant 
bacterial infections found in patients intubated with silver-coated ETTs (p=0.48). 
The study had two major limitations.  Foremost was the limited sample size 
(N=93).  A larger sample size would have strengthened the findings.  The second 
limitation was that the study was a retrospective study of the NASCENT study.  
Retrospective studies do not prove a direct cause and effect relationship.   
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This study was critically appraised using the CASP tool (Appendix B-5).  This 
retrospective cohort analysis of the randomized NASCENT trial addressed whether or not 
there was an association between silver-coated ETTs and reduced mortality for patients 
who developed VAP.  No significant differences in demographics or risk factors between 
the control group and the intervention group were reported prior to the study.  Study 
personnel were blinded to the control/intervention groups and followed antibiotic 
guidelines for administration protocols.  Unfortunately, it is not clear what other VAP 
reduction strategies, such as ventilation strategies, VAP bundles and/or medications were 
implemented during the study.  No treatment effect was reported.  However, group 
designation was found to be a predictor of mortality with a 95% confidence interval.   
All study participants were accounted for in the results.  The results of the study 
were consistent with similar studies throughout this systematic review.  It is unclear if all 
pertinent outcomes were reported during this study.  The authors cite a limitation of the   
inability to prove “cause and effect” between silver-coated ETTs leading to a reduction in 
patient mortality rates.  The benefits of this study (60% reduction in mortality rate for the 
intervention group) outweigh the harms/costs.   
A cross study analysis was completed with the CASE worksheets (Appendix C 
and D).  The cross study analysis looks across all studies to determine if there are 
similarities and/or differences in the findings of each study.  All five studies included in 
this systematic review provided summaries that were specific to the scope of this review.  
Nearly all, with the exception of the Rello et al., offered transparency to the reader.  All 
studies provided appropriately cited recommendations but unfortunately, the 
recommendations were dated.  Two studies included in this systematic review were 
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completed on or prior to 2006.  The most current studies were authored by Afessa et al. 
(2010), Kollef et al. (2008), and Berra et al (2008).  The summaries of all studies were 
unbiased.  The most significant study and results included in this systematic review are 
from Kollef et al. (2008).  Based on the large sample size and scope of the study, the 
results and summary provide detailed data that allows the reader to gauge the accuracy of 
the intervention (silver-coated ETT) with less potential for bias.  
The most significant finding across the studies was a reduction in VAP rates for 
the intervention group.  Each study reported that the intervention group had either fewer 
patients diagnosed with VAP, a reduction in colonization throughout the ETT/breathing 
circuit/lungs, or a reduction in mortality rates for patients who were diagnosed with VAP. 
Next, summary and conclusions will be presented. 
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Summary and Conclusions 
 A systematic review was conducted to determine whether silver-coated ETTs 
were effective at reducing the incidence of VAP when compared to standard ETTs.  A 
comprehensive literature review was conducted using CINAHL, OVID and PubMed.  
The literature review focused on ventilator-associated pneumonia, ETTs, silver-
sulfadiazine, and VAP.  An abundance of literature was found pertaining to VAP and 
silver-sulfadiazine individually.  However, information linking these topics was limited.   
After identifying inclusion and exclusion criteria and using the PRISMA 
flowchart, five studies were identified.  Data collection tables that identified key variables 
for each of the individual studies were developed and completed.  Then, each study was 
critically appraised using the The Critical Appraisal Skills Programme (CASP) tool.  The 
Critical Appraisal Skills Programme helped determine if the study was valid, what the 
results meant and if the results were useful.  It was also used to screen the studies in a 
structured manner so that a determination could be made regarding the validity of the 
data reported within the study.   
Following the critical appraisal, a cross-study analysis was completed with the 
CASE worksheet.  The Critical Appraisal Skills Programme was used to gauge 
transparency of the study, understand the scope of the study, identify any potential bias, 
and review the author’s recommendations following the results.  Findings across the five 
studies were also compared and contrasted.  
After extensively reviewing and appraising the studies, Kollef et al. (2008). 
Afessa et al. (2010) and Rello et al. (2006) provided the most relevant data for this 
systematic review since these studies used human subjects and had larger sample sizes.  
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Kollef et al. and Rello et al. conducted their studies at multiple sites.  One methodological 
problem identified from the Kollef et al. and Afessa et al. studies was a lack of 
documentation regarding patient care standards.  Key components of patient treatment 
including frequency of antibiotics, VAP bundles, and additional preventative strategies 
were not clear.   
Both Berra et al. studies (2004 and 2008) provided valuable data for this 
systematic review; however, these were animal studies.  The results were consistent with 
human studies.  While the results are essential to this systematic review, the results of 
animal studies do not have the same significance to researchers as human studies.  One 
methodological limitation to the Berra et al. studies was the absence of treatment effect 
and another limitation was a question of benefit from the study.  The question of benefit 
stems from the fact that all subjects involved in the Berra et al. studies were euthanized at 
the conclusion of the study.   
All studies reported a reduction or absence of bacteria within the breathing circuit, 
ETT or lungs of the subjects from the intervention group as compared to the control 
group.  These findings were consistent across all studies.  One landmark study, Kollef et 
al. (2008) not only found a 35.9% relative risk reduction in microbiologically confirmed 
cases of VAP for the intervention group, but also reported that it took significantly longer 
for the intervention group to develop VAP (p <.005).  In addition to reduced colonization, 
Afessa et al. (2010) reported a reduction in mortality rate for patients who were in the 
intervention group n=5 (14%) that developed VAP compared to the control group n=20 
(36%). 
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There were several limitations throughout this systematic review.  One of the 
limitations was the number of studies available that met the inclusion criteria.  Only five 
were identified as appropriate based on the inclusion criteria and thus additional research 
is needed.  Another limitation was the age of some of the studies, including Berra et al. 
performed in 2004 and Berra et al. from 2008.  Although the study was not current, the 
results of the study were consistent with more recent studies.  One additional limitation 
was the subjects in two of the studies were not human.  Berra et al. (2004) and Berra et al. 
(2008) studies were conducted on Dorset sheep.   
In summary, the results of the studies included in this systematic review 
concluded that silver-coated ETTs effectively reduce the incidence of VAP.  Findings 
were consistent across the studies.    
Next, the recommendations and implications for advanced practice nursing will 
be discussed.   
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Recommendations and Implications for Advanced Nursing Practice 
Ventilator-associated pneumonia is an expensive and dangerous complication of 
mechanical ventilation.  Ventilator-associated pneumonia prevention is a national patient 
safety standard.  When patients develop VAP, they require longer periods of intubation 
and mechanical ventilation.  Endotracheal tubes increase the risk of developing 
pneumonia by suppressing innate protective airway reflexes (Miller et al., 2014).  A 
microbiologically confirmed case of VAP also prolongs hospital stays, increases the cost 
of the hospitalization, requires increased hospital services and increases the risk of death.   
As care-providers for acutely ill patients throughout the operating rooms, 
intensive care units and emergency rooms, Certified Registered Nurse Anesthetists 
(CRNAs) must advocate for additional strategies to prevent VAP for patients that remain 
intubated following procedures.  One of those strategies is using products impregnated 
with silver.  Silver-coated ETTs can reduce the bacterial colonization of ETTs, breathing 
circuits and a patient’s lungs. 
Education and training by CRNAs should focus on identifying patients pre-
operatively that are likely to need prolonged mechanical ventilation.  These patients are at 
high-risk for developing VAP.  While evidence-based interventions such as elevation of 
the head of the bed, prophylactic stress ulcer medication, oral care with chlorhexidine, 
and prophylactic deep vein thrombus injections remain the most common interventions 
used to reduce the development of VAP in the ICU, CRNAs can intervene even earlier by 
identifying these patients and consulting with the surgeon to determine if post-operative 
intubation is likely.  
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 Certified Registered Nurse Anesthetists are in a key position to advocate on 
patients’ behalf for the use of silver-coated ETTs as a proactive approach to reduce the 
risk of developing VAP for those who are likely to remain intubated for greater than 24 
hours.  By educating caregivers about the benefits of silver-coated ETTs for patients 
requiring prolonged intubation following surgery, CRNAs can help improve patient 
outcomes, reduce costs associated with hospital admissions, and reduce the risk of death 
in patients who develop VAP.   
Certified Registered Nurse Anesthetists should be involved with policy 
development related to VAP, silver-coated ETTs and prevention strategies.  As CRNAs, 
our impact on patient care should not be limited to the OR.  As master’s educated 
providers of care, CRNAs are trained to review and interpret research.  Interpreting and 
validating study results with the assistance of tools such as PRISMA, CASP, and CASE 
are foundational to policy development, which provide the framework for improvements 
to patient care.  Input regarding evidence-based treatment interventions and improving 
patient outcomes are needed.  The CRNA can also advocate for policy at the national 
level via participation in professional organizations 
Further research is needed to confirm the results reported in this systematic 
review.  Research should focus on patient outcomes following intubation with silver-
coated ETTs, any adverse outcomes, and financial considerations that may occur as a 
result of implementing a policy related to intubations with silver-coated ETTs for patients 
requiring prolonged intubation following surgery. 
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Certified Registered Nurse Anesthetists are in a unique position to advocate for 
patients, educate staff about treatment strategies, and develop policy based on evidence-
based practice.  Due to the expanding role of CRNAs across the healthcare spectrum, it is 
critical CRNAs remain current with medical research, medical innovation, and treatment 
strategies.    
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Appendix A 
Table A-1. 
 
Berra, L., De Marchi, L., Yu, Z. X., Laquerriere, P., Baccarelli, A., & Kolobow, T. (2004). Endotracheal tubes coated with antiseptics 
decrease bacterial colonization of the ventilator circuits, lungs, and endotracheal tube. Anesthesiology: The Journal of the American 
Society of Anesthesiologists, 100(6), 1446-1456. 
Study Design Site/Sample 
 
 
Patient Risk 
Factors Prior to 
Intubation 
Duration of 
Intubation 
Outcomes of 
Intubation 
Limitations 
Randomized-
controlled 
study. 
 
Control group:  
n = 8 with 
standard 
uncoated ETTs. 
 
Study group:    
n = 8 with silver 
coated ETTs 
National 
Institutes of 
Health Animal 
Research 
Laboratory 
(Bethesda, 
Maryland). 
 
Subjects were  
N = 16 Sheep, 
female Dorset  
 
Median body  
weight = 30.5kg  
(range = 25-
37kg). 
 
Microscopic 
and 
No predetermined 
risk factors based 
on laboratory data 
and chest 
radiograph 3 days 
prior to the study 
 
Subjects had not 
received any 
antibiotics for a 
minimum of 4 
weeks prior to the 
study. 
 
 
  
 
Intubation = 24 
hours with 
mechanical 
ventilation. 
 
Intubation and 
securement of 
airway was 
completed on first 
attempt (without 
difficulty) for all  
N 16 subjects. 
 
Respiratory and 
hemodynamic 
parameters, core 
body temperature, 
arterial blood gases, 
and urinary output 
Following the study, 
an autopsy was 
conducted and 
included tissue 
samples from the 
trachea, larynx, 
bronchi, and the 5 
lobes of the lungs.   
 
 
Bacterial growth 
within the ETT and 
ventilator circuit of 
the “study group” 
was prevented in 7 
of the 8 eight 
subjects and greatly 
reduced for the 
eighth subject when 
After 24 hours of 
mechanical 
ventilation, subjects 
were euthanized. 
This prevented the 
subjects from 
developing 
pneumonia (which 
likely would have 
occurred with 
bacterial 
colonization within 
the lower 
respiratory tract).  
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microbiologic 
studies were 
performed by 
observers who 
were blinded to 
each group. 
 
Sheep placed in 
prone position 
to simulate 
human 
positioning  
 
  
were monitored.  
Parenteral nutrition 
and fluid 
replacements were 
provided as needed. 
 
Microbiologic 
sampling was done 
every 8 hours and 
included blood 
samples and a swab 
of the internal lumen 
of the ETT (to detect 
bacterial growth). 
Mucus and 
secretions from the 
inner lumen of the 
ETTs were gram-
stained and analyzed 
with light 
microscopy 
 
No systemic or 
topical antibiotics 
were used. 
 
During the study all 
subjects were free of 
fever, leukocytosis, 
and chest 
radiographic 
changes. 
compared to the 
control group. 
 
Study group =  
7 out of 8 were free 
of bacterial 
colonization 
throughout the ETT. 
 
Control group = 
bacterial 
colonization of the 
ETT, ventilator 
circuit, and lower 
respiratory tract.  
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Table A-2. 
 
Berra, L., Kolobow, T., Laquerriere, P., Pitts, B., Bramati, S., Pohlmann, J., ... & Baccarelli, A. (2008). Internally coated endotracheal 
tubes with silver sulfadiazine in polyurethane to prevent bacterial colonization: a clinical trial. Intensive Care Medicine, 34(6), 1030. 
 
Study Design Site/Sample Patient Risk Factors 
Prior to Intubation 
Duration of 
Intubation  
Results Limitations 
Randomized 
Controlled Trial 
 
Dorset Sheep 
mechanically 
ventilated  
Laboratory-
National Institute of 
Health (Bethesda, 
Maryland) 
 
N= 8 
Silver coated ETT  
(n=4) 
Standard ETT 
(n=4) 
Healthy upon 
enrollment based 
on clinical findings, 
lab values, and 
chest radiographs 
throughout the 
intubation period 
 
Intubation 
successful on 1st 
attempt for all 
participants 
24 hours Autopsy-12 biopsy 
samples (50 mg 
each) 
5 (1 from each lung 
lobe) 
5 (lobar bronchi) 
1 (2cm above 
carina) 
1 (middle of ETT) 
 
Standard ETT-
lower respiratory 
tract  
(p < .01) and 
ventilator tubing 
extensively 
colonized (p = 
.003) 
 
Silver coated ETT- 
no colonization 
Study limited to 24 
hours 
 
8 subjects 
 
Microscopy and 
bacteriology 
findings difficult 
for the reader to 
quantify  
(example: 5.0 × 
105– 4.5 × 108) 
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found on ventilator 
tubing  
 
Microscopic 
findings within the 
standard ETT-thick 
and dense secretion 
layer (50-750 
micrometers thick) 
and extensive 
bacterial 
colonization 
 
Silver coated ETT-
thin mucus layer  
(0-450 micrometers 
thick) and no 
bacterial 
colonization 
 
Presence of bacteria 
within ETT 
Standard ETT 3 out 
of 4 
Silver coated ETT 0 
out of 4 
(p = 0.14) 
P values calculated using Wilcoxon-Mann-Whitney and Fisher’s exact test 
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Table A- 3. 
Rello, J., Kollef, M., Diaz, E., Sandiumenge, A., del Castillo, Y., Corbella, X., & Zachskorn, R. (2006). Reduced burden of bacterial 
airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Critical Care 
Medicine, 34(11), 2766-2772. 
Study Design Site/Sample Patient risk factors 
prior to intubation 
Duration of 
Intubation 
Results Limitations 
Randomized 
Controlled Trial 
utilizing allocation 
concealment  
 
Single blind study 
 
 
ICU patients 18 
years and older 
(mean age 64.6) 
 
N = 155   
 
34 excluded (6 not 
intubated and 28 
intubated less than 
24 hours) 
 
121 intubated for 
minimum 24 hours 
 
61 with silver 
coated ETT/60 with 
standard ETT 
Antibiotic exposure 
within past 14 days 
RIC (Respiratory 
Infection Control)  
Silver ETT= 32 
Standard ETT = 30 
 
Risk factors for 
VAP during 
previous 30 days 
include previous 
intubations, 
surgery, trauma, 
use of muscle 
relaxants, 
continuous 
sedation, smoking, 
Minimum of 24 
hours 
 
Silver device had 
delayed microbial 
colonization 
compared to 
standard ETT  
(p .02) 
 
Silver ETT had 
bacterial burden 
found in tracheal 
aspirates 
 
Silver tube showed 
delayed inter-lumen 
colonization 1.8 
days for RIC device 
compared to 3.2 
No “blinding” of 
outcome 
assessment 
(potential for 
detection bias) 
 
No blinding of 
participants and 
personnel (potential 
for performance 
bias) 
 
ICU staff may have 
bias due to inability 
to “blind” them as 
the ETTs are 
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4 Hospitals-1 in the 
United States  
(n = 56) and 3 in 
Spain (n = 99) 
 
 
coma, alcohol 
abuse (p .09) 
Silver ETT = 19 
Standard ETT = 28 
 
Enteral nutrition 
Silver ETT = 42 
Standard ETT = 45 
 
Parenteral nutrition 
Silver ETT = 12  
Standard ETT = 8 
 
days for standard 
ETT  
(p .02) 
 
 
different in 
appearance 
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Table A-4. 
Kollef, M. H., Afessa, B., Anzueto, A., Veremakis, C., Kerr, K. M., Margolis, B. D., ... & Restrepo, M. I. (2008). Silver-coated 
endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA, 300(7), 805-813. 
Study Design Site/Sample  Risk factors prior to 
intubation  
Duration of 
Intubation 
Results Limitations 
A prospective, 
randomized, 
single-blind 
controlled 
study. 
 
Each site was 
given 
numbered 
envelopes that 
contained a 
randomization 
card for each 
study 
participant. 
 
Microbiology 
lab personnel 
and study 
investigators 
were blinded 
Fifty-four medical 
centers throughout 
North America 
between 2002-
2006. 
 
9417 patients were 
screened for the 
study. 
 
N = 2003 patients 
that were expected 
to require 
mechanical 
ventilation for 
greater than 24 
hours were 
identified and 
randomized for the 
study. 
 
Smoker (n = 121 with 
silver-coated ETT;  
n = 113 with standard 
ETT). 
 
Immunodeficiency (n = 
184 patients who had the 
silver-coated ETT and  
n = 186 who had the 
standard ETT). 
 
COPD (n = 89 patients 
that had the silver-coated 
ETT and n = 122 patients 
that had the standard 
ETT) 
 
 
> n 24 hours. With a 95% confidence 
rating, n = 37 patients 
with the silver-coated 
ETT were diagnosed with 
microbiologically 
confirmed cases of VAP 
(4.8%). 
  
n = 56 patients with 
standard ETT were 
diagnosed with 
microbiologically 
confirmed cases of VAP 
(7.5%).   
 
Findings suggest a 35.9% 
relative risk reduction in 
the development of VAP 
for patients intubated 
greater than 24 hours. 
 
Only patients able 
to consent were 
included in the 
study.  This 
prevented patients 
who required 
emergent 
intubations, those 
with a change in 
mental status, and 
other high risk 
patients from 
participating in the 
study. These 
patients are highly 
susceptible to 
developing VAP. 
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to group 
data/specifics. 
 
 
 
 
 
 
n = 766 with 
silver-coated ETT. 
 
n = 743 with 
standard ETT. 
 
Human subjects 
were used for this 
study. 
 
Patients with silver-coated 
ETT had substantial 
reduction in diagnosed 
cases of VAP. 
 
Patients with silver-coated 
ETT took longer to 
develop VAP (10 days) 
 n = 27/766 than patients 
who had the standard ETT 
n = 50/743 (P = 0.005) 
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Table A-5. 
Afessa, B., Shorr, A. F., Anzueto, A. R., Craven, D. E., Schinner, R., & Kollef, M. H. (2010). Association between a silver-coated 
endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia. CHEST Journal, 137(5), 1015-1021. 
Study Design Site/Sample Patient risk factors prior to 
intubation 
Duration of 
Intubation 
Results Limitations 
Retrospective 
cohort 
analysis for 
patients who 
developed 
VAP in 
NASCENT 
study 
(N 93) 
 
Stepwise 
multivariate 
logistic 
regression 
N 93 with 
microbiologically 
confirmed VAP 
 
Silver ETT n = 
37 
Mean age 59.8 
 
Standard ETT  
n = 56 
Mean age 63.3 
 
No significant 
demographic 
differences 
between groups 
Silver ETT 
COPD = 5 
Immunodeficiency = 8 
Emergency surgery/trauma = 3 
Inappropriate antibiotics = 6 
Coma = 0 
 
Standard ETT 
COPD = 7 
Immunodeficiency = 9 
Emergency surgery/trauma = 6 
Inappropriate antibiotics = 9 
Coma = 1  
Greater than 
24 hours 
Mortality rate for 
VAP patients 
with silver ETT 
14% (n =5) 
 
Mortality rate for 
VAP with 
standard ETT 
36% (n=20) 
P = 0.03 
 
Only variable 
that altered 
mortality rate 
was treatment 
group (silver 
ETT vs standard 
ETT) 95% CI 
 
Retrospective studies 
do not prove a cause 
and effect relationship 
(silver vs standard 
ETT) 
 
Small sample size (N 
93) 
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Silver ETT = 13 
developed 
potentially 
multidrug 
resistant bacteria 
 
Control group = 
25 developed 
potentially 
multidrug 
resistant bacteria  
(P = 0.48) 
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Appendix B 
Critical Appraisal Skills Programme (CASP) Tables 
Table B-1. 
Berra, L., De Marchi, L., Yu, Z. X., Laquerriere, P., Baccarelli, A., & Kolobow, T. 
(2004). Endotracheal tubes coated with antiseptics decrease bacterial colonization of the 
ventilator circuits, lungs, and endotracheal tube. Anesthesiology: The Journal of the 
American Society of Anesthesiologists, 100(6), 1446-1456. 
 
Question Yes Can’t 
Tell 
No 
1)  Did the review address a clearly focused question?     
Yes.  The study focused on bacterial colonization of the 
lungs, ETT, and ventilator circuit when an ETT coated with 
silver-sulfadiazine was used.   
X   
2)  Was the assignment of patients to treatments 
randomized? 
Yes.  The authors conducted a controlled-randomized study 
of female Dorset sheep (N=16).  The sheep were separated 
into two groups.  The control group was intubated with a 
standard ETT (n=8) and the intervention group was intubated 
with a silver-coated ETT (n=8).  The study was conducted at 
the National Institutes of Health Animal Research Laboratory 
in Bethesda, Maryland. 
X   
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3)  Were patients, health workers, and study personnel 
blinded? 
Yes.  All microbiologic and microscopic studies were 
completed by blinded personnel. 
X   
4)  Were the groups similar at the start of the trial? 
Yes.  Based on laboratory data and chest radiographs three 
days prior to the study, no predetermined risk factors were 
identified in either group.  Patients had not received any 
antibiotics for a minimum of four weeks prior to the study. 
X   
5)  Aside from the experimental intervention, were the 
groups treated equally? 
Yes.  All were induced with 7mg/kg Ketamine and 
maintained on Sodium Pentobarbital/Pancuronium.  
Ventilator settings were comparable for both groups.  Patient 
monitoring consisted of respiratory and hemodynamics, 
temperature, blood gas analysis, urine output, blood cell 
counts, and chest radiographs.  Parenteral nutrition and fluid 
replacement were given as needed to both groups.   
Patients were placed in prone position.  No antibiotics were 
administered during the study for either group. 
X   
6)  Were all the patients who entered the trial properly 
accounted for at its conclusion? 
X   
56 
 
Yes.  All 16 Dorset sheep were accounted for and included in 
the data/results.  The results from the control group (n=8) and 
the intervention group (n=8) were gathered through autopsy.  
Twelve tissue samples weighing approximately 50mg each 
were gathered from the trachea, larynx, bronchi, and the five 
lung lobes.  
7)  How large was the treatment effect? 
Treatment effect was not reported.   
  X 
8)  How precise was the estimate of the treatment effect? 
Although treatment effect was not included, other findings 
were very precise.  The intervention group demonstrated 
elimination/reduction of bacterial colonization within the 
silver-sulfadiazine ETTs and near prevention of bacterial 
colonization of the lung for the intervention group.  After 24 
hours of intubation, the inner-lumen of the intervention 
groups’ ETT was free of bacterial colonization in seven of 
the sheep (P < 0.0001).  
 X  
9)  Can the results be applied in your context or to the 
local population? 
Can’t tell.  The data and primary outcome provide 
comparable results to other studies included throughout this 
systematic review.  However, because the subjects are not 
humans, the results are less valued than human studies. 
 X  
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10)  Were all clinically important outcomes considered? 
Yes.  The outcomes assessed throughout this systematic 
review were addressed in this study.  However, because the 
subjects were euthanized immediately following 24 hours of 
intubation and mechanical ventilation, they did not develop 
pneumonia.  The only data generated from the study is 
specific to bacterial colonization of the ventilator circuit, 
ETTs, and lungs.  
 X  
11)  Are the benefits worth the harms and costs? 
Can’t tell.  The data/results provide a foundation for future 
research.  However, the euthanization of the 16 Dorset sheep 
following the study may be ethically unacceptable to certain 
populations.  
 X  
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Table B-2. 
Berra, L., Kolobow, T., Laquerriere, P., Pitts, B., Bramati, S., Pohlmann, J., ... & 
Baccarelli, A. (2008). Internally coated endotracheal tubes with silver sulfadiazine in 
polyurethane to prevent bacterial colonization: a clinical trial. Intensive Care 
Medicine, 34(6), 1030. 
 
Question Yes Can’t 
Tell 
No 
1)  Did the review address a clearly focused question?   
Yes.  The review addressed whether or not silver-coated 
ETTs could effectively prevent bacterial colonization of the 
respiratory tubing and lower respiratory tract.  
X   
2)  Was the assignment of patients to treatments 
randomized?   
Yes.  The study was a randomized controlled trial conducted 
in a laboratory at the National Institute of Health.  The 
subjects were female Dorset sheep (N=8).  Four subjects 
were given the standard ETT (n=4) and the remaining were 
part of the intervention group (n=4).  
X   
3)  Were patients, health workers, and study personnel 
blinded? 
Can’t tell.  There is no documentation about the process of 
data/sample collections.   
 X  
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4)  Were the groups similar at the start of the trial? 
Yes.  All subjects were healthy upon enrollment in the study 
based on lab values, clinical findings, and chest X-rays.  
During the 24-hour study, no fevers, purulent drainage from 
the ETTs, abnormalities on chest X-ray, or leukocytosis was 
found. 
X   
5)  Aside from the experimental intervention, were the 
groups treated equally? 
Can’t tell.  The trail does not provide specifics regarding 
standardization of treatment throughout the 24-hour study.  
One documented detail of significance was that all subjects 
were successfully intubated on the first attempt.  
 X  
6)  Were all the patients who entered the trial properly 
accounted for at its conclusion? 
Yes.  All were accounted for.  
X   
7)  How large was the treatment effect? 
No treatment effect was reported.  
  X 
8)  How precise was the estimate of the treatment effect? 
No treatment effect was reported.  However, the silver-coated 
ETTs significantly reduced bacterial colonization within the 
ventilator tubing and lower respiratory tract of the 
intervention group compared to the control group.  
  X 
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Additionally, no bacteria were found within the lumen of the 
silver-coated ETTs while three of the standard ETTs were 
found to have bacterial colonization.  Subjects with standard 
ETTs were found to have colonization of the lower 
respiratory tract and the ventilator tubing was extensively 
colonized.   
9)  Can the results be applied in your context or to the 
local population? 
Can’t tell.  The data and results align with comparable studies 
used for this systematic review.  However, the subjects are 
non-human so the results are less valuable than similar 
studies that used human subjects.  
 X  
10)  Were all clinically important outcomes considered? 
Can’t tell.  The main outcome was identified and answered 
by the authors. However, the subjects were euthanized 
following the study which eliminated the possibility of 
developing VAP.  While the authors were able to present data 
showing a reduction in colonization, the study stops short of 
showing a reduction in VAP development with the use of 
silver-coated ETTs.   
 X  
11)  Are the benefits worth the harms and costs? 
Can’t tell.  The study, conducted and approved by the 
National Institutes of Health, does provide useful data for 
 X  
61 
 
future researchers regarding antimicrobial effects of silver-
coated ETTs.  However, healthy animal subjects were used 
for this study and ultimately euthanized.  The ethicality of 
animal research is an individual decision.    
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Table B-3 
Rello, J., Kollef, M., Diaz, E., Sandiumenge, A., del Castillo, Y., Corbella, X., & 
Zachskorn, R. (2006). Reduced burden of bacterial airway colonization with a novel 
silver-coated endotracheal tube in a randomized multiple-center feasibility study. Critical 
Care Medicine, 34(11), 2766-2772. 
 
Question Yes Can’t 
Tell 
No 
1)  Did the review address a clearly focused question? 
Yes.  The question the study addressed was whether a silver-
coated ETT could feasibly and safely reduce bacterial 
colonization of the lungs and tracheal aspirates.  The study 
focused on ICU patients that were intubated for a minimum 
of 24 hours.  The results suggested the silver-coated ETT 
offered delayed microbial colonization compared to standard 
ETT (P .02).  Additionally, the silver-coated ETT showed 
delayed inter-lumen colonization-1.8 days for silver-coated 
ETT compared to 3.2 days for standard ETT (P .02). 
X   
2)  Was the assignment of patients to treatments 
randomized? 
Yes.  Patients were assigned to a block-randomization list by 
validated software.  The study was a prospective, randomized 
controlled trial that utilized allocation concealment.  The 
X   
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study was a single blind study conducted at four hospitals, 
three in Spain and one in the United States.  N= 155.  Of the 
155, 121 were intubated for a minimum of 24 hours. 
3)  Were patients, health workers, and study personnel 
blinded? 
No.  Both the microbiological lab personnel and the 
investigators were blinded.  Investigators were blinded to 
block length and the microbiology lab was blinded to the 
control/intervention groups. However, the ICU staff may 
have been biased due to inability to “blind” them as the ETTs 
were slightly different in appearance (silver-coating).  
Additionally, there was no “blinding” of outcome assessment 
which could have lead to potential detection bias. 
  X 
4)  Were the groups similar at the start of the trial? 
Can’t tell.  Baseline characteristics and demographics were 
similar in both groups.  All patients were free of respiratory 
infections, bronchiectasis, hematemesis, hemoptysis, cystic 
fibrosis, immunosuppression, and exhibited no allergy to 
silver compounds.  All patients/legally authorized 
representative were required to sign an informed consent 
prior to beginning the study.  However, the indication for 
intubation was not consistent for all patients and could 
impact patient prognosis/study outcomes. 
 X  
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5)  Aside from the experimental intervention, were the 
groups treated equally? 
No.  The process of infection control throughout the study 
was not standardized between hospitals.  Additionally, the 
process of quantifying ETT colonization was different in 
Spain (semi-quantitative) than it was in the United States 
(quantitative).  Both groups were intubated with high 
volume/low pressure ETTs ranging in size from 7-9mm 
internal diameters.  The only difference between the ETTs 
used for the groups was that the intervention groups’ ETT 
was coated with silver.  Each group had daily swab cultures 
from the inner lumen.  Tracheal colonization was gathered 
and cultured by sterile suction catheters. 
  X 
6)  Were all the patients who entered the trial properly 
accounted for at its conclusion? 
Yes.  The intervention group (n=61) and the control group 
(n=60) were accounted for in the results. 
X   
7)  How large was the treatment effect? 
No treatment effect was reported. 
  X 
8)  How precise was the estimate of the treatment effect? 
Can’t tell.  No treatment effect was documented.  However, 
the intervention group had delayed microbial colonization 
within the ETT.  Other significant outcomes identified were 
 X  
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reduced bacterial burden found in the tracheal aspirates of the 
intervention group as well as delayed inter-lumen 
colonization (P. 02).  The outcomes were measured using 
multiple measuring tools (Wilcoxon-Mann-Whitney for 
between group differences and Fisher’s Exact for between 
group differences in colonization). 
9)  Can the results be applied in your context or to the 
local population? 
Can’t tell.  The results of this study are relevant for this 
systematic review.  However, without greater standardization 
of infection control practices throughout all hospitals studied, 
the potential for bias is significant. 
 X  
10)  Were all clinically important outcomes considered? 
Yes.  All clinically important outcomes were reported.  The 
study addressed whether or not silver-coated ETTs could 
delay microbial colonization of the lungs, tracheal aspirate, 
and inter-lumen of the ETT (reduction in airway bacterial 
burden). 
X   
11)  Are the benefits worth the harms and costs? 
Yes.  No adverse outcomes were reported during the study. 
Patients in the intervention group had a reduction in bacterial 
airway colonization. 
X   
Table B-4. 
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Kollef, M. H., Afessa, B., Anzueto, A., Veremakis, C., Kerr, K. M., Margolis, B. D., ... & 
Restrepo, M. I. (2008). Silver-coated endotracheal tubes and incidence of ventilator-
associated pneumonia: the NASCENT randomized trial. JAMA, 300(7), 805-813. 
 
Question Yes Can’t 
Tell 
No 
1) Did the review address a clearly focused question?   
Yes.  The trial addressed the question of whether or not a 
silver-coated ETT would reduce the incidence of 
microbiologically confirmed VAP.   
X   
2)  Was the assignment of patients to treatments 
randomized? 
Yes.  The trial was a prospective, randomized, single-blind 
controlled study.  The study was conducted at 54 medical 
centers throughout North America.  Each medical center’s 
institutional review board approved the study.  Screening for 
the trial involved 9417 patients.  Of the 9417, 7414 were 
excluded because they were either unable to consent or were 
unlikely to require more than 24 hours of mechanical 
ventilation.   N=2003 were randomized and expected to 
require intubation and mechanical ventilation for a minimum 
of 24 hours.  Groups were randomly selected (control vs 
X   
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intervention) by validated software. The control group 
contained n=743.  The intervention group contained n=766. 
3)  Were patients, health workers, and study personnel 
blinded? 
Yes.  All microbiology lab personnel and study investigators 
were blinded to the control/intervention groups as well as the 
data and specifics related to their hospitalization.  
X   
4)  Were the groups similar at the start of the trial? 
Yes.  All participants of the study were at least 18 years old.  
Mean age of the intervention group was 60.9.  Mean age of 
the control group was 62.  Exclusions included current 
enrollment in another study that could conflict with this one, 
cystic fibrosis, pregnancy, previous intubation within the past 
30 days, severe hemoptysis, and sensitivity to silver products.  
Both groups had similar patient co-morbidities including 
COPD, smoking, emergent surgery, trauma, and 
immunodeficiency. 
X   
5)  Aside from the experimental intervention, were the 
groups treated equally? 
Can’t tell.  The study does not detail specifics regarding 
patient care.  The study does detail specific patient data that 
was collected such as BAL via tracheal suctioning, oral care, 
daily chest radiographs, vital signs, and clinical signs of 
 X  
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VAP.  However, no specifics are provided regarding patient 
treatment.  
6)  Were all the patients who entered the trial properly 
accounted for at its conclusion? 
Yes.  There were 2,003 that were entered and eligible to be in 
the study.  494 were excluded because they were either not 
intubated or intubated for less than 24 hours.  The remaining 
1,509 are accounted for. 
X   
7)  How large was the treatment effect?  
The treatment effect (silver-coated ETTs) reported a 35.9% 
relative risk reduction in the incidence of VAP.  Additionally, 
patients with silver-coated ETTs took longer to develop VAP 
(10 days) n = 27/766 than patients who had the standard ETT 
n = 50/743. 
X   
8)  How precise was the estimate of the treatment effect? 
 The treatment effect, reported as microbiologically 
confirmed cases of VAP, was 4.8% (37/766) for the 
intervention group and 7.5% (56/743).  Microbiologically 
confirmed cases of VAP for the control group was 7.5% 
(56/743). 
X   
9)  Can the results be applied in your context or to the 
local population? 
X   
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Yes.  The trial concluded that silver-coated ETTs offered 
significant reductions in both the incidence of VAP and 
delayed the onset of a VAP diagnosis when compared to 
standard ETTs. 
10)  Were all clinically important outcomes considered? 
Yes.  All the pertinent clinical outcomes from this trial were 
reported.  The main outcome (diagnosis of VAP) and onset 
were identified and clearly stated.  Demographics and 
baseline characteristics for both the control group and the 
intervention group were presented in table format-making it 
easy for the reader to visualize and interpret. 
X   
11)  Are the benefits worth the harms and costs? 
Yes.  No adverse outcomes were reported from the trial.  The 
benefits exceed the harms and costs of the trial. 
X   
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Table B-5. 
Afessa, B., Shorr, A. F., Anzueto, A. R., Craven, D. E., Schinner, R., & Kollef, M. H. 
(2010). Association between a silver-coated endotracheal tube and reduced mortality in 
patients with ventilator-associated pneumonia. CHEST Journal, 137(5), 1015-1021. 
 
Question Yes Can’t 
Tell 
No 
1)  Did the review address a clearly focused question?  
Yes.  The review questioned whether or not there was an 
association between silver-coated ETTs and reduced 
mortality for patients who developed VAP.  Mortality was 
reduced in VAP patients from 20/56 (36%) in control group) 
to 5/37 (14%) in the intervention group) N=93. 
X   
2)  Was the assignment of patients to treatments 
randomized?   
Yes.  This was a retrospective cohort analysis or the 
NASCENT study (patients were randomized for the 
NASCENT study). 
X   
3)  Were patients, health workers, and study personnel 
blinded? 
Yes.  The authors who assessed the appropriateness of 
treatment and antibiotics were blinded to the treatment 
X   
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groups.  Additionally, they followed antibiotic guidelines for 
empirical antibiotic therapy for VAP patients. 
4)  Were the groups similar at the start of the trial? 
Yes.  There were no statistically significant differences in 
demographics or risk factors between the control group and 
intervention group.  Each group had approximately the same 
percentage of patients with pre-existing conditions such as 
COPD, immunodeficiency, trauma, emergent surgeries, 
inappropriate administration of antibiotics, and coma.  
X   
5)  Aside from the experimental intervention, were the 
groups treated equally? 
Can’t tell.  There are not details on frequency of antibiotics, 
VAP bundles, types of medications given during intubation 
and ventilation, or preventative strategies.  
 X  
6)  Were all the patients who entered the trial properly 
accounted for at its conclusion? 
Yes.  There were N=93 patients identified and studied during 
this retrospective cohort analysis.  The control group 
included 56 and the intervention group 37. 
X   
7)  How large was the treatment effect? 
There was no specific mention of the treatment effect.  
However, group designation was a predictor of mortality and 
 X  
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silver-coated ETTs were associated with reduced mortality 
rates for patients with VAP.  
8)  How precise was the estimate of the treatment effect? 
The predictor of mortality given by an odds ratio was 95% 
confidence interval when comparing silver-coated ETTs to 
standard ETTs. 
 X  
9)  Can the results be applied in your context or to the 
local population? 
Yes.  These results directly apply to this systematic review.  
The results are derived from the “hallmark study” in this 
research, the NASCENT study.     
X   
10)  Were all clinically important outcomes considered? 
Can’t tell.  While mortality was the primary outcome 
identified throughout the study, the authors cite limitations 
within their study by not presenting any proof of “cause and 
effect” with the silver-coated ETTs and reduced patient 
mortality.  There may have been unidentified risk factors 
(cause) that contributed to the pathophysiologic demise 
(effect) of patients in one or both groups (control and 
intervention).   
 X  
11)  Are the benefits worth the harms and costs? 
Yes.  Only patients able to consent were included for this 
study.  In the absence of this research, all of these patients 
X   
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would have been intubated with standard ETTs.  This study 
identified a 60% reduction in the mortality rate for patients 
with silver-coated ETTs who developed VAP compared to 
the standard ETTs (control group).    
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Appendix C 
 
Critical Appraisal for Summaries of Evidence (CASE) Worksheet  
 
for Individual Studies 
 
Table C-1. 
Berra, L., De Marchi, L., Yu, Z. X., Laquerriere, P., Baccarelli, A., & Kolobow, T. 
(2004). Endotracheal tubes coated with antiseptics decrease bacterial colonization of the 
ventilator circuits, lungs, and endotracheal tube. Anesthesiology: The Journal of the 
American Society of Anesthesiologists, 100(6), 1446-1456. 
 
 
 
 
 
Critical Appraisal for Summaries of Evidence (CASE) Worksheet 
Questions Evaluation 
Summary Topic 
Is the summary specific in scope and 
application? 
Yes  
 
Summary Methods 
Is the authorship of the summary 
transparent? 
Yes 
 
Are the reviewer(s)/editor(s) of the 
summary transparent? 
Yes  
Are the research methods transparent and 
comprehensive? 
Yes 
Is the evidence grading system transparent 
and translatable?  
Yes 
Summary Content 
Are the recommendations clear? Not completely 
  
Are the recommendations appropriately 
cited? 
Yes  
Are the recommendations current? No 
Is the summary unbiased? Yes  
 
Summary Application  
Can this summary be applied to your 
patient(s)? 
No 
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Table C-2. 
Berra, L., Kolobow, T., Laquerriere, P., Pitts, B., Bramati, S., Pohlmann, J., ... & 
Baccarelli, A. (2008). Internally coated endotracheal tubes with silver sulfadiazine in 
polyurethane to prevent bacterial colonization: a clinical trial. Intensive Care 
Medicine, 34(6), 1030. 
 
. 
 
 
 
 
 
 
 
 
Critical Appraisal for Summaries of Evidence (CASE) Worksheet 
Questions Evaluation 
Summary Topic 
Is the summary specific in scope and 
application? 
Yes  
 
Summary Methods 
Is the authorship of the summary 
transparent? 
Yes 
 
Are the reviewer(s)/editor(s) of the 
summary transparent? 
 Yes 
 
Are the research methods transparent and 
comprehensive? 
 Yes 
Is the evidence grading system transparent 
and translatable?  
Yes 
 
Summary Content 
Are the recommendations clear? Yes  
  
Are the recommendations appropriately 
cited? 
Yes 
  
Are the recommendations current? Not completely 
Is the summary unbiased? Yes 
Summary Application  
Can this summary be applied to your 
patient(s)? 
 Not completely 
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Table C-3. 
 
Rello, J., Kollef, M., Diaz, E., Sandiumenge, A., del Castillo, Y., Corbella, X., &  
 
Zachskorn, R. (2006). Reduced burden of bacterial airway colonization with a novel  
 
silver-coated endotracheal tube in a randomized multiple-center feasibility study. Critical  
 
Care Medicine, 34(11), 2766-2772 
 
 
 
 
 
 
 
 
 
 
 
 
Critical Appraisal for Summaries of Evidence (CASE) Worksheet 
Questions Evaluation 
Summary Topic 
Is the summary specific in scope and 
application? 
Yes 
Summary Methods 
Is the authorship of the summary 
transparent? 
Yes 
Are the reviewer(s)/editor(s) of the 
summary transparent? 
Not completely 
Are the research methods transparent and 
comprehensive? 
Not completely 
 
Is the evidence grading system transparent 
and translatable?  
Yes 
Summary Content 
Are the recommendations clear? Yes 
 
Are the recommendations appropriately 
cited? 
Yes 
  
Are the recommendations current? No 
Is the summary unbiased? Yes 
Summary Application  
Can this summary be applied to your 
patient(s)? 
Not completely 
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Table C-4. 
Kollef, M. H., Afessa, B., Anzueto, A., Veremakis, C., Kerr, K. M., Margolis, B. D., ... & 
Restrepo, M. I. (2008). Silver-coated endotracheal tubes and incidence of ventilator-
associated pneumonia: the NASCENT randomized trial. JAMA, 300(7), 805-813. 
 
 
 
 
 
 
 
 
 
 
 
 
Critical Appraisal for Summaries of Evidence (CASE) Worksheet 
Questions Evaluation 
Summary Topic 
Is the summary specific in scope and 
application? 
Yes  
 
Summary Methods 
Is the authorship of the summary 
transparent? 
Yes 
Are the reviewer(s)/editor(s) of the 
summary transparent? 
Yes  
Are the research methods transparent and 
comprehensive? 
Not completely  
 
Is the evidence grading system transparent 
and translatable?  
Not completely 
 
Summary Content 
Are the recommendations clear? Yes  
Are the recommendations appropriately 
cited? 
Yes 
  
Are the recommendations current? Not completely 
Is the summary unbiased? Yes 
Summary Application  
Can this summary be applied to your 
patient(s)? 
Yes  
 
78 
 
Table C-5 
Afessa, B., Shorr, A. F., Anzueto, A. R., Craven, D. E., Schinner, R., & Kollef, M. H. 
(2010). Association between a silver-coated endotracheal tube and reduced mortality in 
patients with ventilator-associated pneumonia. CHEST Journal, 137(5), 1015-1021. 
 
 
 
 
 
 
 
 
 
 
 
 
Critical Appraisal for Summaries of Evidence (CASE) Worksheet 
Questions Evaluation 
Summary Topic 
Is the summary specific in scope and 
application? 
Yes  
 
Summary Methods 
Is the authorship of the summary 
transparent? 
Yes  
 
Are the reviewer(s)/editor(s) of the 
summary transparent? 
Yes 
  
Are the research methods transparent and 
comprehensive? 
Yes 
 
Is the evidence grading system transparent 
and translatable?  
No 
 
Summary Content 
Are the recommendations clear? Yes 
  
Are the recommendations appropriately 
cited? 
Yes 
  
Are the recommendations current? Yes 
Is the summary unbiased? Yes 
 
Summary Application  
Can this summary be applied to your 
patient(s)? 
No 
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Appendix D 
 
Critical Appraisal for Summaries of Evidence (CASE) Worksheet  
 
for Cross Study Analysis 
 
 
 
 
Critical Appraisal for Summaries of Evidence (CASE) Worksheet *Numbers in 
evaluation correspond with those assigned to articles in data extrapolation chart* 
Questions Evaluation 
Summary Topic 
Is the summary specific in scope and 
application? 
Yes- 1, 2, 3, 4, 5 
Not completely- 
No- 
Summary Methods 
Is the authorship of the summary 
transparent? 
Yes- 1, 2, 3, 4, 5 
Not completely- 
No- 
Are the reviewer(s)/editor(s) of the 
summary transparent? 
Yes- 1, 2, 4, 5 
Not completely- 3 
No- 
Are the research methods transparent and 
comprehensive? 
Yes- 1, 2, 5 
Not completely- 3, 4 
No- 
Is the evidence grading system transparent 
and translatable?  
Yes- 1, 2, 3 
Not completely- 4 
No- 5 
Summary Content 
Are the recommendations clear? Yes- 2, 3, 4, 5 
Not completely-1  
No- 
Are the recommendations appropriately 
cited? 
Yes- 1, 2, 3, 4, 5 
Not completely- 
No- 
Are the recommendations current? Yes- 5 
Not completely- 2, 4 
No- 1, 3 
Is the summary unbiased? Yes- 1, 2, 3, 4, 5  
Not completely 
No 
Summary Application  
Can this summary be applied to your 
patient(s)? 
Yes- 4 
Not completely- 2, 3 
No- 1, 5 
